```html

Zollinger–Ellison‑type Peptide Excess

Overview

Zollinger–Ellison‑type peptide excess refers to an overproduction of gastrin‑releasing peptide (GRP) and related hormones (most commonly gastrin) that stimulate the stomach to secrete large amounts of gastric acid. The condition is most frequently seen in patients with a gastrin‑producing tumor called a gastrinoma, which is a type of pancreatic‑duodenal neuroendocrine tumor (PNET). When the tumor secretes excessive gastrin, it drives the parietal cells of the stomach to release too much acid, leading to severe peptic ulcer disease, diarrhea, and malabsorption.

Although the classic disease is called Zollinger‑Ellison syndrome (ZES), the term “Zollinger–Ellison‑type peptide excess” is sometimes used in clinical literature to describe the biochemical state—high circulating gastrin—regardless of whether a tumor is found.

• Who it affects: Adults aged 30‑60 are most commonly diagnosed, but cases in teenagers and children are reported, especially in hereditary syndromes.
• Prevalence: Gastrinomas are rare, accounting for <≈1% of all pancreatic tumors. An estimated 0.5–2 cases per million people develop ZES each year worldwide (Mayo Clinic, 2023).
• Gender: Slight male predominance (approximately 55 % male).

Symptoms

The presenting complaints stem from acid hypersecretion and the downstream effects on the gastrointestinal (GI) tract. Symptoms can vary from mild dyspepsia to life‑threatening bleeding.

Gastro‑esophageal symptoms

• Heartburn / Reflux – burning sensation behind the breastbone, often worse after meals.
• Epigastric pain – gnawing or burning pain in the upper abdomen, sometimes radiating to the back.
• Acidic regurgitation – sour taste in the mouth.

Peptic ulcer disease

• Multiple ulcers in the duodenum, jejunum, or even the distal stomach.
• Ulcers that are refractory to standard proton‑pump inhibitor (PPI) therapy.
• Signs of ulcer complications:
  • Vomiting of coffee‑ground material (indicative of upper GI bleeding).
  • Black, tarry stools (melena) or bright red blood per rectum (hematochezia).

Lower GI symptoms

• Chronic watery diarrhea – occurs in up to 70 % of patients; the high acid load inactivates pancreatic enzymes and damages the intestinal lining.
• Steatorrhea – fatty, foul‑smelling stools caused by malabsorption of fat.
• Abdominal cramping and bloating.

Systemic manifestations

• Weight loss despite normal or increased food intake.
• Fatigue and anemia (often iron‑deficiency from chronic bleeding).
• Electrolyte disturbances such as low magnesium or potassium due to diarrheal losses.

Causes and Risk Factors

Primary cause – Gastrinoma

Over 90 % of Zollinger‑Ellison‑type peptide excess cases are caused by a gastrin‑secreting neuroendocrine tumor. These tumors arise from the “G” cells of the pancreas or duodenum and are usually benign (70‑80 %) but can be malignant in 20‑30 % of patients.

Associated syndromes

• Multiple Endocrine Neoplasia type 1 (MEN 1) – an inherited disorder that predisposes to pancreatic neuroendocrine tumors, parathyroid hyperplasia, and pituitary adenomas. Up to 25 % of MEN 1 patients develop gastrinomas.
• Familial Zollinger‑Ellison syndrome – rare autosomal‑dominant inheritance.

Risk factors

• Genetic predisposition (MEN 1 mutation, familial ZES).
• History of chronic atrophic gastritis or pernicious anemia – can cause secondary hypergastrinemia, though usually with lower acid output.
• Long‑standing use of proton‑pump inhibitors (PPIs) may raise gastrin levels, but this does not cause true peptide excess; it’s a confounder in testing.
• Age > 30 years and male sex modestly increase detection rates.

Diagnosis

Diagnosing Zollinger–Ellison‑type peptide excess requires a combination of biochemical, imaging, and endoscopic studies.

Biochemical testing

• Fasting serum gastrin level – > 1,000 pg/mL (or > 10 × upper limit of normal) strongly suggests gastrinoma, especially when gastric pH < 2.
• Secretin stimulation test – administration of secretin paradoxically raises gastrin in gastrinoma patients; a rise > 120 pg/mL is diagnostic.
• Measurement of gastric pH (via nasogastric aspirate) – confirms acid hypersecretion (pH < 2).

Imaging studies

• Endoscopic ultrasound (EUS) – high‑resolution view of the pancreas and duodenum; sensitivity 80‑90 % for tumors < 2 cm.
• Multiphasic contrast‑enhanced CT or MRI – locates primary tumor and assesses for metastasis (especially liver).
• Somatostatin receptor scintigraphy (OctreoScan) or Gallium‑68 DOTATATE PET/CT – detects neuroendocrine tumors with high receptor expression; essential for staging.

Endoscopic evaluation

• Upper endoscopy (EGD) – visualizes ulcer disease, may obtain biopsies to exclude H. pylori or malignancy.
• In some centers, spyglass cholangiopancreatoscopy is used to directly visualize small duodenal lesions.

Diagnostic criteria summary

1. Elevated fasting gastrin + gastric pH < 2 → suspect gastrinoma.
2. Confirm with secretin stimulation test.
3. Localize tumor with EUS, CT/MRI, and/or somatostatin receptor imaging.
4. Stage disease (TNM) to guide therapy.

Treatment Options

Management aims to (1) control acid hypersecretion, (2) eradicate or control the tumor, and (3) address nutritional deficits.

Acid‑suppression therapy

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole 60‑80 mg daily or equivalent; titrated to symptom control and normalized gastric pH (> 4). PPIs are the cornerstone; <90 % of patients achieve symptom relief.
• Histamine‑2 receptor antagonists (H2RAs) – can be added for breakthrough symptoms, but less effective alone.

Surgical treatment

• Curative resection – enucleation or pancreaticoduodenectomy (Whipple) for localized tumors; offers 5‑year disease‑free survival > 70 % when no metastasis.
• Debulking surgery – reduces tumor burden in metastatic disease; may improve symptom control.

Medical therapy for the tumor

• Somatostatin analogues (octreotide, lanreotide) – bind SSTR2 receptors, inhibiting gastrin release; useful in unresectable or metastatic disease.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) approved for advanced pancreatic neuroendocrine tumors.
• Chemotherapy – streptozocin‑based regimens for aggressive, poorly differentiated tumors.
• Peptide receptor radionuclide therapy (PRRT) – Lutetium‑177‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; improves progression‑free survival (NETTER‑1 trial).

Lifestyle and supportive measures

• Small, low‑fat meals; avoid spicy, acidic, or caffeine‑rich foods that aggravate ulcer pain.
• Maintain adequate hydration and oral rehydration solutions if diarrhea is severe.
• Supplement iron, vitamin B12, calcium, and fat‑soluble vitamins (A, D, E, K) when malabsorption is documented.

Living with Zollinger–Ellison‑type Peptide Excess

Daily management tips

• Medication adherence – take PPIs 30 minutes before breakfast; never skip doses.
• Monitor symptoms – keep a diary of pain, heartburn, stool frequency, and any bleeding.
• Regular follow‑up – every 3–6 months for gastrin levels, endoscopy, and imaging as advised by your endocrinologist or gastroenterologist.
• Nutrition – work with a registered dietitian; a high‑protein, moderate‑carbohydrate diet helps offset protein loss from chronic diarrhea.
• Stress management – stress can exacerbate ulcer pain; consider relaxation techniques, yoga, or counseling.

Psychosocial aspects

Chronic disease can cause anxiety and depression. Connecting with support groups (e.g., NETpatient, American Gastroenterological Association forums) has been shown to improve quality of life (Cleveland Clinic, 2022).

Prevention

Because most cases are tumor‑driven and often genetic, primary prevention is limited. However, you can reduce secondary risk factors and improve outcomes:

• Avoid long‑term, high‑dose PPI use without medical supervision – it can mask early symptoms and delay diagnosis.
• Screen individuals with MEN 1 or a family history of ZES with periodic fasting gastrin tests and imaging.
• Test and eradicate Helicobacter pylori infection – while not a cause, it can worsen ulcer disease.
• Adopt a balanced diet low in irritants (caffeine, alcohol, nicotine) to protect the gastric mucosa.

Complications

If untreated or inadequately controlled, Zollinger–Ellison‑type peptide excess can lead to serious health problems:

• Refractory peptic ulcer disease – may result in perforation, peritonitis, or gastric outlet obstruction.
• Gastrointestinal bleeding – acute hemorrhage can be life‑threatening.
• Malnutrition – chronic diarrhea and malabsorption cause protein‑calorie deficiency, weight loss, and electrolyte imbalance.
• Duodenal or jejunal strictures – from repeated ulcer healing.
• Metastatic neuroendocrine tumor spread – especially to the liver, lungs, or bone, which worsens prognosis.
• Bone demineralization – chronic acid exposure may impair calcium absorption leading to osteoporosis.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
2. American College of Gastroenterology. “Guidelines for the Diagnosis and Management of Gastric Acid Hypersecretion.” 2022.
3. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Gastrinomas and Zollinger‑Ellison Syndrome.” 2022.
4. World Health Organization. “Neuroendocrine Tumors: Classification and Management.” WHO Press, 2021.
5. Cleveland Clinic. “Living with Neuroendocrine Tumors – Patient Resources.” 2022.
6. Strosberg J, et al. “Phase 3 Trial of 177Lu‑DOTATATE for Mid‑gut Neuroendocrine Tumors.” New England Journal of Medicine. 2017;376:125–135.
7. J. Yao, et al. “Management of Gastrinomas and Zollinger‑Ellison Syndrome.” Gastroenterology. 2020;158(1):12‑23.

```